FinscoFinsco

Pfizer (US.PFE)

Capital Allocation Audit · Period: 2010 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.PFE · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion83.3%↑
ROE3.0%↓
Cash Conversion97.3%↑
D/E Ratio0.71→
Gross Margin75.4%→
US.PFE (Pfizer) | YoY: 2026 Q1 vs 2025 Q1


Metric           Value  YoY
---------------------------
FCF Conversion   83.3%    ↑
ROE               3.0%    ↓
Cash Conversion  97.3%    ↑
D/E Ratio         0.71    →
Gross Margin     75.4%    →
Key Metrics
US.PFE (Pfizer) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
---------------------------
FCF Conversion 83.3% ↑
ROE 3.0% ↓
Cash Conversion 97.3% ↑
D/E Ratio 0.71 →
Gross Margin 75.4% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies